Castle Biosciences Files 8-K on Financials
Ticker: CSTL · Form: 8-K · Filed: 2025-01-13T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, regulation-fd, exhibits
Related Tickers: CSTL
TL;DR
Castle Biosciences dropped an 8-K on Jan 12th covering financials and operations.
AI Summary
Castle Biosciences, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing also includes information related to Regulation FD disclosure and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Friendswood, Texas.
Why It Matters
This filing provides investors with crucial updates on Castle Biosciences' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual risks.
Key Players & Entities
- Castle Biosciences, Inc. (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- January 13, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Friendswood, Texas (location) — Address of principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
This 8-K filing pertains to the 'Results of Operations and Financial Condition' of Castle Biosciences, Inc., as of January 12, 2025.
When was this 8-K filing submitted to the SEC?
The filing was submitted on January 13, 2025.
What is the primary business of Castle Biosciences, Inc. according to the filing?
The filing lists Castle Biosciences, Inc. under the Standard Industrial Classification code 8071, which corresponds to 'SERVICES-MEDICAL LABORATORIES'.
Where are Castle Biosciences, Inc.'s principal executive offices located?
The principal executive offices of Castle Biosciences, Inc. are located at 505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546.
What other items are covered in this 8-K filing besides financial condition?
In addition to 'Results of Operations and Financial Condition,' this 8-K filing also includes information on 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
Filing Stats: 662 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2025-01-13 06:58:16
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share CSTL The Nasdaq Glo
Filing Documents
- cstl-20250112.htm (8-K) — 30KB
- cstlprelimresultsq42024.htm (EX-99.1) — 26KB
- castlebiosciencesq42024p.htm (EX-99.2) — 10KB
- castlebiosciencesq42024p001.jpg (GRAPHIC) — 109KB
- castlebiosciencesq42024p002.jpg (GRAPHIC) — 182KB
- castlebiosciencesq42024p003.jpg (GRAPHIC) — 142KB
- castlebiosciencesq42024p004.jpg (GRAPHIC) — 126KB
- castlebiosciencesq42024p005.jpg (GRAPHIC) — 79KB
- castlebiosciencesq42024p006.jpg (GRAPHIC) — 66KB
- castlebiosciencesq42024p007.jpg (GRAPHIC) — 55KB
- image_0.jpg (GRAPHIC) — 39KB
- 0001447362-25-000012.txt ( ) — 1300KB
- cstl-20250112.xsd (EX-101.SCH) — 2KB
- cstl-20250112_lab.xml (EX-101.LAB) — 22KB
- cstl-20250112_pre.xml (EX-101.PRE) — 13KB
- cstl-20250112_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 12, 2025, Castle Biosciences, Inc. (the "Company") issued a press release announcing certain preliminary performance results for the fourth quarter of 2024 and for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 12, 2025, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company. The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release issued January 12 , 202 5 . 99.2 Slide presentation. 104 Inline XBRL for the cover page of this Current Report on Form 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CASTLE BIOSCIENCES, INC. By: /s/ Frank Stokes Frank Stokes Chief Financial Officer Date: January 12, 2025